Michel Velez

791 total citations
16 papers, 110 citations indexed

About

Michel Velez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michel Velez has authored 16 papers receiving a total of 110 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Michel Velez's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (6 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Michel Velez is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (6 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Michel Velez collaborates with scholars based in United States and Brazil. Michel Velez's co-authors include Edgardo S. Santos, Luis E. Raez, Cesar A. Perez, Mauricio A. Escobar, Georges Azzi, Lazaros J. Lekakis, Aurelio Castrellon, Carlos Carracedo, Jennifer W. Carlisle and Martin Dietrich and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and BioMed Research International.

In The Last Decade

Michel Velez

15 papers receiving 108 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michel Velez United States	6	71	54	50	24	9	16	110
Brad Somer United States	4	47 0.7×	49 0.9×	38 0.8×	18 0.8×	5 0.6×	4	99
Cody Weimholt United States	7	91 1.3×	63 1.2×	67 1.3×	33 1.4×	10 1.1×	15	168
Hanna Ronkainen Finland	6	67 0.9×	65 1.2×	34 0.7×	42 1.8×	13 1.4×	11	162
Ana Remírez Spain	7	76 1.1×	37 0.7×	48 1.0×	48 2.0×	4 0.4×	9	151
Xuemei Zuo United States	5	69 1.0×	63 1.2×	53 1.1×	24 1.0×	6 0.7×	5	136
Mohammad Atiq United States	6	54 0.8×	88 1.6×	64 1.3×	26 1.1×	8 0.9×	21	155
Marni B. McClure Japan	5	67 0.9×	41 0.8×	29 0.6×	41 1.7×	3 0.3×	7	123
Nicole Gull United States	4	93 1.3×	25 0.5×	24 0.5×	34 1.4×	7 0.8×	4	114
Laura Gibson United States	6	59 0.8×	78 1.4×	31 0.6×	24 1.0×	11 1.2×	6	150
Egmidio Medina United States	7	64 0.9×	106 2.0×	22 0.4×	24 1.0×	6 0.7×	10	173

Countries citing papers authored by Michel Velez

Since Specialization

Citations

This map shows the geographic impact of Michel Velez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Velez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Velez more than expected).

Fields of papers citing papers by Michel Velez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Velez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Velez. The network helps show where Michel Velez may publish in the future.

Co-authorship network of co-authors of Michel Velez

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Velez. A scholar is included among the top collaborators of Michel Velez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Velez. Michel Velez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Dietrich, Martin & Michel Velez. (2024). Larotrectinib in NTRK3 fusion–positive metastatic secretory carcinoma of the breast: A case study. SHILAP Revista de lepidopterología. 17. 100334–100334. 2 indexed citations

Raez, Luis E., Carlos Carracedo, Leylah Drusbosky, et al.. (2021). EGFR L718V (+)/T790M (–) as a Mechanism of Resistance in Patients with Metastatic Non–small-cell Lung Cancer with EGFR L858R Mutations. Clinical Lung Cancer. 22(6). e817–e819. 4 indexed citations

Raez, Luis E., Kathleen D. Danenberg, Aurelio Castrellon, et al.. (2018). Use of cell-free circulating RNA (cfRNA) levels in plasma and expression of HER2 and PD-L1 to monitor disease status in metastatic cancer patients.. Journal of Clinical Oncology. 36(15_suppl). e15013–e15013. 1 indexed citations

Castrellon, Aurelio, et al.. (2017). Initial Response to Therapy with Fulvestrant and Cyclin-Dependent Kinase 4/6 Inhibitor in a Male with Stage IV Breast Cancer. 2(1). 1–5. 1 indexed citations

Castrellon, Aurelio, et al.. (2017). Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer. Hematology/Oncology and Stem Cell Therapy. 11(1). 30–33. 1 indexed citations

Raez, Luis E., Kathleen D. Danenberg, Brian Hunis, et al.. (2017). P2.03b-039 Cell-Free (cf) DNA and cfRNA levels in Plasma of Lung Cancer Patients Indicate Disease Status and Predict Progression. Journal of Thoracic Oncology. 12(1). S959–S959. 1 indexed citations

Raez, Luis E., Kathleen D. Danenberg, Aurelio Castrellon, et al.. (2017). Correlation of cell-free circulating DNA, RNA, and PD-L1 from plasma with clinical response in patients with metastatic lung and breast cancers.. Journal of Clinical Oncology. 35(15_suppl). 11550–11550.

Azzi, Georges, et al.. (2014). Isocitrate dehydrogenase mutations in chondrosarcoma. Current Opinion in Oncology. 26(4). 403–407. 10 indexed citations

Perez, Cesar A., Michel Velez, Luis E. Raez, & Edgardo S. Santos. (2014). Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation. Lung Cancer. 84(2). 110–115. 36 indexed citations

10.

Velez, Michel, et al.. (2013). Safety and Efficacy of Pemetrexed in Maintenance Therapy of Non-Small Cell Lung Cancer. SHILAP Revista de lepidopterología. 1 indexed citations

11.

Velez, Michel, et al.. (2013). New Prospects for Drug Development: The Hedgehog Pathway Revealed. Focus on Hematologic Malignancies. Future Oncology. 9(5). 681–697. 6 indexed citations

12.

Velez, Michel, Luis E. Raez, Cesar A. Perez, et al.. (2012). Abnormal elevation of erythrocyte mean corpuscular volume (MCV) in non-small cell lung cancer (NSCLC) patients treated with maintenance pemetrexed-based chemotherapy.. Journal of Clinical Oncology. 30(15_suppl). e17564–e17564. 1 indexed citations

13.

Velez, Michel, et al.. (2012). Safety and Efficacy of Pemetrexed in Maintenance Therapy of Non-Small Cell Lung Cancer. Clinical Medicine Insights Oncology. 6. 117–24. 7 indexed citations

14.

Escobar, Mauricio A., et al.. (2011). The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer. BioMed Research International. 2011(1). 806506–806506. 26 indexed citations

15.

Perez, Cesar A., et al.. (2010). EGF receptor in lung cancer: a successful story of targeted therapy. Expert Review of Anticancer Therapy. 10(10). 1577–1587. 12 indexed citations

16.

Velez, Michel, et al.. (2010). Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. Expert Review of Anticancer Therapy. 10(4). 549–557. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact